$CINC News
Last published 2y ago
- 2y agoAUPHAPLSCMPITPTX+5Axonis Therapeutics Announces $115 Million Series A FinancingPR NewswireAxonis Therapeutics, a biotechnology company focused on the development of novel neuromedicines, announced today the successful completion of an...
- 2y agoAKROAPLSAUPHHRMY+5venBio Raises $528 Million Venture Capital Fund Focused on Life Science CompaniesBusiness Wire- venBio promotes Yvonne Yamanaka, Ph.D. to Partner venBio today announced the closing of venBio Global Strategic Fund V ("venBio Fund V"), its fifth life sciences venture capital fund, exceeding its target and
- 3y agoIMPLCINCImpel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business UpdateGlobeNewswireTrudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call
- 3y agoCDTXELVNIMPLPEAR+55AM Ventures Celebrates 20th FDA Product Approval Investing in Breakthrough ScienceGlobeNewswireSAN FRANCISCO and BOSTON, March 23, 2023 (GLOBE NEWSWIRE) -- 5AM Ventures is pleased that the U.S. Food and Drug Administration (FDA) approved REZZAYO™ (rezafungin for injection) for the treatment of candidemia
- 3y agoCINCCinCor Pharma Announces Receipt of Minutes from End-of-Phase 2 Meeting with the U.S. Food and Drug Administration on Planned Phase 3 Program of BaxdrostatGlobeNewswireWALTHAM, Mass., Feb. 21, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. ("CinCor" or the "Company") announced today completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration ("FDA") on the
- 3y agoALBOCINCGMGIPAYAMoore Kuehn Encourages GMGI, CINC, ALBO, and PAYA Investors to Contact Law FirmGlobeNewswireNEW YORK, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the
- 3y agoALBOCINCGMGIPAYAMoore Kuehn Encourages GMGI, CINC, ALBO, and PAYA Investors to Contact Law FirmPR NewswireNEW YORK, Jan. 22, 2023 /PRNewswire/ -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following
- 3y agoCINCCinCor Pharma to be Acquired by AstraZenecaGlobeNewswireWALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor.
- 3y agoCINCCinCor Pharma Announces Topline Data for Phase 2 HALO Trial Evaluating Selective Aldosterone Synthase Inhibitor Baxdrostat in Uncontrolled HypertensionGlobeNewswirePrimary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in Systolic Blood Pressure (SBP) 12.6 mmHg placebo-adjusted reduction in SBP with 2 mg baxdrostat in a pre-specified subgroup
- 3y agoCINCCinCor Pharma to Present at Upcoming Piper Sandler and Evercore ISI Investor ConferencesGlobeNewswireWALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) today announced that company management will present at the following investor conferences in November: Event:Piper Sandler 34th
- 4y agoCINCCinCor Pharma to Present at Upcoming Jefferies London Healthcare ConferenceGlobeNewswireWALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) today announced that company management will participate at the Jefferies London Healthcare Conference taking place on November 15-17,
- 4y agoCINCCinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data on Baxdrostat in Treatment-Resistant Hypertension at the 2022 American Heart Association Scientific SessionsGlobeNewswireAldosterone and renin biomarker activity clinically demonstrate how baxdrostat mechanistically achieves selective blood pressure lowering effects with no impact on cortisol 20.3 mmHg reduction in systolic blood
- 4y agoCINCCinCor Pharma Announces Publication in the New England Journal of Medicine of Phase 2 BrigHtn Data on Selective Aldosterone Synthase Inhibitor Baxdrostat in Treatment-Resistant HypertensionGlobeNewswireClinically significant and dose-dependent reduction in blood pressure with baxdrostat Highly selective mechanism of action with no meaningful impact on cortisol supports first-in-class potential Potential treatment for
- 4y agoCINCCinCor Pharma Appoints Michael W. Kalb, Executive Vice President and Chief Financial OfficerGlobeNewswireWALTHAM, Mass., Nov. 07, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. ("CinCor") announced the appointment of Michael W. Kalb as Executive Vice President and Chief Financial Officer (CFO), effective November 4. An
- 4y agoCINCCorrecting and Replacing: CinCor Reports Third Quarter Financial Results and Provides Corporate UpdateGlobeNewswireWALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. is re-issuing its earnings press release for the third quarter ended September 30, 2022, issued on November 3, 2022 at 8:00 am ET, to correct and
- 4y agoCINCCinCor Reports Third Quarter Financial Results and Provides Corporate UpdateGlobeNewswirePositive topline Phase 2 BrigHtn data demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension Late-breaking presentation of
- 4y agoCINCCinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat at the Upcoming American Society of Nephrology Kidney Week 2022GlobeNewswireWALTHAM, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) today announced that the company will present Phase 1 clinical data on its lead product candidate, baxdrostat, as part of a poster
- 4y agoCINCCinCor Pharma Announces Publication of Phase 1 Multiple Ascending Dose Study Data in Hypertension ResearchGlobeNewswireWALTHAM, Mass., Oct. 21, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) today announced the publication of Phase 1 clinical data for baxdrostat, a highly selective, once daily, oral small molecule inhibitor
- 4y agoCINCCinCor Pharma Announces Oral Presentation of Phase 1 Data for Baxdrostat at the Upcoming 29th International Society of Hypertension 2022 ConferenceGlobeNewswireWALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) today announced that the company will present Phase 1 clinical data on its lead product candidate, baxdrostat, as part of an oral
- 4y agoCINCCinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data for Baxdrostat in Treatment-Resistant Hypertension at the Upcoming 2022 American Heart Association Scientific SessionsGlobeNewswireWALTHAM, Mass., Sept. 28, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) today announced that the company will present Phase 2 data from its BrigHtn trial evaluating baxdrostat in patients with treatment-resistant hypertension as part of th
- 4y agoAKUSCINCFIXXIONS+1Arthur Tzianabos, Ph.D., June Lee, MD FACCP, and Joseph Loscalzo, MD, Ph.D. Join 5AM VenturesGlobeNewswireSAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently depl
- 4y agoCINCCinCor Pharma to Participate at Upcoming September Investor ConferencesGlobeNewswireWALTHAM, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) today announced that company management will participate at the following investor conferences: Citi's 17th Annual BioPharma Conference taking place September 6 - 8, 20
- 4y agoCINCCinCor Pharma Announces Presentation of Phase 1 Clinical Data for Baxdrostat at the Upcoming European Society of Cardiology 2022 CongressGlobeNewswireWALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) today announced that the company will present Phase 1 clinical data on lead candidate baxdrostat as part of a poster presentation at the upcoming European Society of Ca
- 4y agoCINCCinCor Pharma Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional SharesGlobeNewswireWALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. ("CinCor") (NASDAQ:CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, baxdrostat, for the treatment of hypertension and other cardio
- 4y agoCINCCinCor Pharma Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireWALTHAM, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. ("CinCor") (NASDAQ:CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, baxdrostat, for the treatment of hypertension and other cardio
- 4y agoCINCCinCor Pharma Announces Proposed Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireWALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. ("CinCor") (NASDAQ:CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, baxdrostat, for the treatment of hypertension and other cardio
- 4y agoCINCCinCor Reports Second Quarter Financial Results and Provides Corporate UpdateGlobeNewswirePositive topline data in the Phase 2 BrigHtn trial, demonstrating clinically meaningful and statistically significant reduction in blood pressure with baxdrostat in treatment-resistant hypertension Completed enrollment in the HALO Phase 2
- 4y agoCINCCinCor Pharma Announces Positive Topline Data for Phase 2 BrigHtn Trial Evaluating Baxdrostat, its Selective Aldosterone Synthase Inhibitor, in Treatment-Resistant HypertensionGlobeNewswireSuccessfully met the primary endpoint in the BrigHtn trial, delivering a 20.3 mmHg reduction in systolic blood pressure (SBP), or an 11 mmHg (p-value < 0.0001) decline on a placebo-adjusted basis, at 2 mg dose Independent Data Review Committee determi
- 4y agoCINCCinCor Pharma Announces Last Patient Randomized in Phase 2 HALO Trial and Initiation of Long-Term Extension Study for Baxdrostat, a Selective Aldosterone Synthase Inhibitor, in Uncontrolled HypertensionGlobeNewswireOpen Label Extension Study Will Evaluate Baxdrostat for Up to 52 Weeks Topline Data for Phase 2 HALO Trial Expected in 2H 2022 Topline Data for Phase 2 BrigHtn Trial Expected in August 2022 WALTHAM, Mass., July 26, 2022 (GLOBE NEWSWIRE)
- 4y agoCINCCinCor Pharma Doses First Patient in Phase 2 FigHTN-CKD Trial Evaluating the Selective Aldosterone Synthase Inhibitor Baxdrostat (CIN-107) in Patients with Uncontrolled Hypertension and Chronic Kidney DiseaseGlobeNewswirefigHTN-CKD is CinCor's fourth ongoing Phase 2 clinical trial evaluating baxdrostat (CIN-107) Initial topline data for figHTN-CKD expected in 2H 2023 WALTHAM, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. ("CinCor") announced today
- 4y agoCINCCinCor Pharma to Present at the Jefferies Healthcare ConferenceGlobeNewswireWALTHAM, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) today announced participation at the Jefferies 2022 Healthcare Conference taking place June 8 - 10 in New York, New York. The CinCor management team will give a corporat
- 4y agoCINCCinCor Pharma to Present at Upcoming Investor ConferencesGlobeNewswireWALTHAM, Mass., May 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) today announced that management will present at the H.C. Wainwright 2022 Global Investment Conference taking place on May 23-26 virtually and in Miami, Florida, and at t
- 4y agoCINCCinCor Reports First Quarter Financial Results and Provides Corporate UpdateGlobeNewswireTopline data for baxdrostat (CIN-107) in BrigHtn Phase 2 trial for treatment-resistant hypertension (rHTN) expected in 2H 2022 Topline data for baxdrostat (CIN-107) in HALO Phase 2 trial for uncontrolled hypertension (uHTN) expected in 2H 2022 Phas
- 4y agoCINCCinCor Pharma to Participate in Jefferies Biotech on the Bay SummitGlobeNewswireWALTHAM, Mass., April 19, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. ("CinCor") today announced its participation in the Jefferies Biotech on the Bay Summit taking place April 26-27 in Miami, Florida. The CinCor management team will participate
- 4y agoCINCCinCor Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate UpdateGlobeNewswireBrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected in 2H 2022 Topline Data from HALO Phase 2 study with CIN-107 for Uncontrolled Hypertension Expected in 2H 2022 Mason Freeman, M.D. named
- 4y agoCINCCinCor Pharma to be Added to Russell 2000® and Russell 3000® IndexesGlobeNewswireBOSTON, March 17, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, toda
- 4y agoCINCCinCor Pharma to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on March 22, 2022GlobeNewswireBOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, toda
- 4y agoCINCCinCor Pharma to Present at the 32nd Annual Oppenheimer Healthcare ConferenceGlobeNewswireBOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases, today
- 4y agoCINCCinCor Pharma Appoints June Lee to Its Board of DirectorsGlobeNewswireBOSTON, Jan. 13, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ:CINC) today announced the appointment of the independent member June Lee, M.D. to the company's Board of Directors. Dr. Lee brings decades of leadership experience in the biotechnolo
- 4y agoCINCCinCor Pharma Announces Pricing of Initial Public OfferingGlobeNewswireBOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. ("CinCor") (NASDAQ:CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal dise